Biocompatibility of heparin-grafted hemodialysis membranes: Impact on monocyte chemoattractant protein-1 circulating level and oxidative status

Hemodialysis International

Volumn 14, Issue 4, 2010, Pages 403-410

  Morena, Marion ^a,b   Jaussent, Isabelle ^c   Chalabi, Lotfi ^d   Bargnoux, Anne Sophie ^a,b   Dupuy, Anne Marie ^a,b   Badiou, Stéphanie ^a,b   Rakic, Claire ^e   Thomas, Michel ^e   Canaud, Bernard ^a,b,d   Cristol, Jean Paul ^a,b  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b UNIV MONTPELLIER   (France)

^c INSERM   (France)

^d AIDER   (France)

^e Hospal International Marketing   (France)

Author keywords

Evodial; Hemodialysis; Heparin coated membrane; Oxidative stress

Indexed keywords

BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; CREATININE; FIBRINOGEN; HOMOCYSTEINE; INTERLEUKIN 6; ISOPROSTANE; LOW MOLECULAR WEIGHT HEPARIN; MONOCYTE CHEMOTACTIC PROTEIN 1; POLYSULFONE; SUPEROXIDE; TUMOR NECROSIS FACTOR ALPHA; UREA;

ADULT; AGED; ARTICLE; ARTIFICIAL KIDNEY; BIOCOMPATIBILITY; BLOOD SAMPLING; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; CREATININE CLEARANCE; DIALYSATE; DIALYSIS MEMBRANE; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; HEPARIN GRAFTED HEMODIALYSIS MEMBRANE; HEPARINIZATION; HUMAN; INFLAMMATION; KIDNEY CLEARANCE; KIDNEY FAILURE; LABORATORY TEST; MALE; MATERIAL COATING; OBSERVATIONAL STUDY; OXIDATIVE STRESS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; TREATMENT DURATION;

AGED; BIOCOMPATIBLE MATERIALS; CHEMOKINE CCL2; FEMALE; HEPARIN; HUMANS; INFLAMMATION MEDIATORS; KIDNEY FAILURE, CHRONIC; KIDNEY, ARTIFICIAL; MALE; MATERIALS TESTING; MEMBRANES, ARTIFICIAL; MIDDLE AGED; OXIDATIVE STRESS; PROSPECTIVE STUDIES; RENAL DIALYSIS;

EID: 77958605861     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2010.00494.x     Document Type: Article

References (22)

1. Jubelirer SJ. Hemostatic abnormalities in renal disease. Am J Kidney Dis. 1985; 5:219-225.
2. Sohal AS, Gangji AS, Crowther MA, Treleaven D. Uremic bleeding: Pathophysiology and clinical risk factors. Thromb Res. 2006; 118:417-422.
3. Canaud B, Mion C, Arujo A, et al. Prostacyclin (epoprostenol) as the sole antithrombotic agent in postdilutional hemofiltration. Nephron. 1988; 48:206-212.
4. Chang JJ, Parikh CR. When heparin causes thrombosis: Significance, recognition, and management of heparin-induced thrombocytopenia in dialysis patients. Semin Dial. 2006; 19:297-304.
5. Bagdade JD, Porte D Jr., Bierman EL. Hypertriglyceridemia. A metabolic consequence of chronic renal failure. N Engl J Med. 1968; 279:181-185.
6. Hottelart C, Achard JM, Moriniere P, et al. Heparin-induced hyperkalemia in chronic hemodialysis patients: Comparison of low molecular weight and unfractionated heparin. Artif Organs. 1998; 22:614-617.
7. Schmer G, Teng LN, Vizzo JE, et al. Clinical use of a totally heparin grafted hemodialysis system in uremic patients. Trans Am Soc Artif Intern Organs. 1977; 23:177-184.
8. Lavaud S, Canivet E, Wuillai A, et al. Optimal anticoagulation strategy in haemodialysis with heparin-coated polyacrylonitrile membrane. Nephrol Dial Transplant. 2003; 18:2097-2104.
9. Chanard J, Lavaud S, Touré F, et al. Assessment of heparin binding to the AN69 ST hemodialysis membrane: I. Preclinical studies. ASAIO J. 2005; 51:342-347.
10. Lavaud S, Paris B, Maheut H, et al. Assessment of the heparin-binding AN69 ST hemodialysis membrane: II. Clinical studies without heparin administration. ASAIO J. 2005; 51:348-351.
11. Chanard J, Karaaslan H, Lavaud S, et al. A new synthetic heparinized hemodialyzer membrane (Abstract). J Am Soc Nephrol. 2008; 19:F-PO1580.
12. Badiou S, Dupuy AM, Descomps B, Cristol JP. Comparison between the enzymatic vitros assay for creatinine determination and three other methods adapted on the Olympus analyzer. J Clin Lab Anal. 2003; 17:235-240.
13. Badiou S, Cristol JP, Jaussent I, et al. Fine-tuning of the prediction of mortality in hemodialysis patients by use of cytokine proteomic determination. Clin J Am Soc Nephrol. 2008; 3:423-430.
14. Delample D, Durand F, Severac A, et al. Implication of xanthine oxidase in muscle oxidative stress in COPD patients. Free Radic Res. 2008; 42:807-814.
15. Ventura E, Durant R, Jaussent A, et al. Homocysteine and inflammation as main determinants of oxidative stress in the elderly. Free Radic Biol Med. 2009; 46:737-744.
16. Cheung AK, Rocco MV, Yan G, et al. Serum beta-2 microglobulin levels predict mortality in dialysis patients: Results of the HEMO study. J Am Soc Nephrol. 2006; 17:546-555.
17. Papayianni A, Alexopoulos E, Giamalis P, et al. Circulating levels of ICAM-1, VCAM-1, and MCP-1 are increased in haemodialysis patients: Association with inflammation, dyslipidaemia, and vascular events. Nephrol Dial Transplant. 2002; 17:435-441.
18. Niu J, Kolattukudy PE. Role of MCP-1 in cardiovascular disease: Molecular mechanisms and clinical implications. Clin Sci (Lond). 2009; 117:95-109.
19. Garcia-de-la-Asuncion J, De Toro P, Planelles V, et al. Bemiparin improves the total antioxidant status in plasma. Eur J Pharmacol. 2009; 602:380-382.
20. Poyrazoglu OK, Dogukan A, Yalniz M, et al. Acute effect of standard heparin versus low molecular weight heparin on oxidative stress and inflammation in hemodialysis patients. Ren Fail. 2006; 28:723-727.
21. Leitienne P, Fouque D, Rigal D, et al. Heparins and blood polymorphonuclear stimulation in haemodialysis: An expansion of the biocompatibility concept. Nephrol Dial Transplant. 2000; 15:1631-1637.
22. Borawski J. Myeloperoxidase as a marker of hemodialysis biocompatibility and oxidative stress: The underestimated modifying effects of heparin. Am J Kidney Dis. 2006; 47:37-41.